Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
COMMODITY trading firm, Trafigura, has paid a record $3 billion (£2.4bn) dividend to its 1,200 private shareholders after registering record profits, reported The Times.
The Singapore-based company booked a £459 million charge for the first half of this year because of what it said was 'systematic fraud' by a group of companies controlled by Indian tycoon Prateek Gupta, including TMT Metals and the UD Trading Group.
Trafigura initiates legal proceedings against Gupta after it alleged there was no nickel in some containers it had bought from his companies.
Despite this, the company’s net profits more than doubled from £1.4bn to £4.4 bn in the six months ended March 31. It also generated earnings before interest, tax, depreciation and amortisation of £6.4bn.
However, revenues fell by 23 per cent to £104.5bn amid a decline in commodity prices and lower trading volumes, The Times report further said.
Trafigura's CEO and executive chairman, Jeremy Weir, emphasised the indispensable role of the industry in achieving a low-carbon economy. With its extensive knowledge in global supply chain management and their investment in low-carbon fuels like hydrogen and transition metals, Trafigura is poised to play a crucial part in facilitating this transition, Weir added.
Trafigura trades billions of barrels of oil and petroleum products every year and is a leading trader of metals and minerals.
Nickel is essential for stainless steel and lithium-ion batteries. For many years, Trafigura has been trading with Gupta companies. However, the trader became suspicious about its cargos when some were delayed last year.
Independent investigators hired by Trafigura discovered lower-value products in a container delivered to Rotterdam. Later, Trafigura clarified no involvement of its employees, while Gupta's representatives assert they are preparing a strong response to the fraud allegations.
Earlier this month, reports said that Gupta plan to ask a London court for a two-week extension to file a challenge to a £497m global freezing order on him.
Last month, a London judge agreed to extend a freezing order on assets of the wife of Gupta, Ginni, in addition to the freezing order which was already in place.
Lawyers for both sides agreed that Ginni was not alleged to have committed any offences, although a Trafigura lawyer added they did not believe she was "a wholly innocent bystander".
The freezing order on Gupta was imposed on April 25 on two assets, a house in Dubai in which the couple are believed to live, and Silver Star SPC, a Cayman Islands investment fund, a court document by Trafigura's lawyers said.
A London court imposed the first freezing order on February 8 on bank accounts and other assets tied to Gupta and seven companies Trafigura said are controlled by him, including in Britain, Singapore, Malaysia and Switzerland.
The group employs more than 8,500 people across 80 offices worldwide and also owns shipping, logistics and industrial operations.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.